Search research articles
Contact Us
Filters
Showing results (161-170 of 492) with videos related to
Page
of 50
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population
Glenn Heller, Karim Fizazi, Robert McCormack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2019
Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer
Adam Sharp, Nuria Porta, Maryou B K Lambros, et al.
British Journal of Cancer
|
July 29, 2010
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
A T Brunetto, D Sarker, D Papadatos-Pastos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2014
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
David Lorente, Diletta Bianchini, Alejo Rodriguez-Vida, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
D Bianchini, D Lorente, A Rodriguez-Vida, et al.
ESMO Open
|
August 2, 2017
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
Saoirse O Dolly, Cristina Migali, Nina Tunariu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
European Urology
|
August 29, 2017
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe
Johann S de Bono, Simon Chowdhury, Susan Feyerabend, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer
Alexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Page
of 50
Search research articles
Search
Showing results (161-170 of 492) with videos related to
Sort By:
Page
of 50
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2016
The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population
Glenn Heller, Karim Fizazi, Robert McCormack, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2019
Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer
Adam Sharp, Nuria Porta, Maryou B K Lambros, et al.
British Journal of Cancer
|
July 29, 2010
A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit
A T Brunetto, D Sarker, D Papadatos-Pastos, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2014
Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer
David Lorente, Diletta Bianchini, Alejo Rodriguez-Vida, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
D Bianchini, D Lorente, A Rodriguez-Vida, et al.
ESMO Open
|
August 2, 2017
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
Saoirse O Dolly, Cristina Migali, Nina Tunariu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 31, 2014
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial
C N Sternberg, J S de Bono, K N Chi, et al.
European Urology
|
August 29, 2017
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe
Johann S de Bono, Simon Chowdhury, Susan Feyerabend, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 12, 2013
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, et al.
Therapeutic Advances in Medical Oncology
|
June 9, 2022
Neutropenia, neutrophilia, and neutrophil-lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer
Alexander Meisel, Ronald de Wit, Stephane Oudard, et al.
Page
of 50